LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
19 hedge funds and large institutions have $48.6M invested in LAVA Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
6% more funds holding
Funds holding: 18 → 19 (+1)
2.73% less ownership
Funds ownership: 34.61% → 31.88% (-2.7%)
49% less capital invested
Capital invested by funds: $95.5M → $48.6M (-$46.8M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$892K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$132K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$65.3K |
| 4 |
Axa
Paris,
France
|
+$60.9K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$26.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.22M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$1.82M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$946K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$674K |
| 5 |
Millennium Management
New York
|
-$482K |
LVTX Hedge Fund Activity: Q3 2021 in Review
19 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q3 2021, worth a combined $48.6M — down 49% from $95.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LVTX positions and 5 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $892K. The largest seller was Wellington Management Group, exiting entirely with an estimated $2.22M sold.
- 19 institutional investors held LAVA Therapeutics (LVTX) as of Q3 2021, up from 18 in Q2 2021.
- Funds reported $48.6M of LAVA Therapeutics stock for Q3 2021, down 49% quarter-over-quarter.
- 6 funds opened new LAVA Therapeutics positions in Q3 2021 and 5 closed out, a net change of +1 holder.
- The largest LAVA Therapeutics buyer in Q3 2021 was Point72 Asset Management, an estimated $892K added.
- The largest LAVA Therapeutics seller in Q3 2021 was Wellington Management Group, an estimated $2.22M sold.
Based on aggregated 13F filings for Q3 2021.